We have located links that may give you full text access.
Excimer laser phototherapeutic keratectomy: long-term results and practical considerations.
Cornea 1997 March
PURPOSE: Our purpose was to evaluate the safety and short- and long-term efficacy of excimer laser phototherapeutic keratectomy (PTK) to treat anterior corneal pathology.
METHODS: Twenty-eight eyes of 24 patients underwent PTK for anterior corneal pathologic conditions with a VISX excimer laser. Preoperative indications included granular dystrophy (six eyes), superficial variant of granular dystrophy (six eyes), and Salzmann's nodular degeneration (five eyes). Three eyes had recurrent erosions, and two eyes had keratoconus nodules. Additional diagnoses included other corneal dystrophies and various corneal scars. Mean follow-up time was 22.5 months (range, 5-44). One eye underwent a repeated PTK for recurrent scarring 1 year after the initial procedure and is included in the results.
RESULTS: The mean time to reepithelialization was 4.2 days (range, 2-11). Corneal smoothness and clarity improved in all patients. Uncorrected visual acuity improved a mean of 1.4 lines (range, -6 to +8 lines) and best corrected visual acuity improved a mean of 2.7 lines (range, -3 to +7 lines). Mean corneal flattening was 2.13 D (range, 7.75. D flatter to 6.5 D steeper). The preoperative goal was achieved in 22 (78.5%) of 28 eyes, with no significant change in five (18%) eyes and functional worsening in one (3.5%) eye. Five eyes developed moderate to significant recurrences of their pathology, including the retreated eye.
CONCLUSION: Excimer laser PTK is safe and effective for the treatment of anterior corneal pathology. Recurrence of pathology, especially corneal dystrophies, do occur with time.
METHODS: Twenty-eight eyes of 24 patients underwent PTK for anterior corneal pathologic conditions with a VISX excimer laser. Preoperative indications included granular dystrophy (six eyes), superficial variant of granular dystrophy (six eyes), and Salzmann's nodular degeneration (five eyes). Three eyes had recurrent erosions, and two eyes had keratoconus nodules. Additional diagnoses included other corneal dystrophies and various corneal scars. Mean follow-up time was 22.5 months (range, 5-44). One eye underwent a repeated PTK for recurrent scarring 1 year after the initial procedure and is included in the results.
RESULTS: The mean time to reepithelialization was 4.2 days (range, 2-11). Corneal smoothness and clarity improved in all patients. Uncorrected visual acuity improved a mean of 1.4 lines (range, -6 to +8 lines) and best corrected visual acuity improved a mean of 2.7 lines (range, -3 to +7 lines). Mean corneal flattening was 2.13 D (range, 7.75. D flatter to 6.5 D steeper). The preoperative goal was achieved in 22 (78.5%) of 28 eyes, with no significant change in five (18%) eyes and functional worsening in one (3.5%) eye. Five eyes developed moderate to significant recurrences of their pathology, including the retreated eye.
CONCLUSION: Excimer laser PTK is safe and effective for the treatment of anterior corneal pathology. Recurrence of pathology, especially corneal dystrophies, do occur with time.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app